Company Description
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases.
Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Chaim Lebovits |
Contact Details
Address: 1325 Avenue of Americas, 28th Floor New York, New York 10019 United States | |
| Phone | 201 488 0460 |
| Website | brainstorm-cell.com |
Stock Details
| Ticker Symbol | BCLI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001137883 |
| CUSIP Number | 10501E201 |
| ISIN Number | US10501E2019 |
| Employer ID | 20-7273918 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chaim Lebovits | President and Chief Executive Officer |
| Dr. Ibrahim Dagher M.D. | Executive Vice President and Chief Medical Officer |
| Uri Yablonka | Executive Vice President, Chief Business Officer, Secretary and Director |
| Dr. Irit Arbel DSc, Ph.D. | Co-Founder and Independent Vice Chair of the Board |
| Alla Patlis CPA, M.B.A. | Interim Chief Financial Officer and Controller |
| Dr. Hartoun Hartounian Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Daniel Offen Ph.D. | Chief Scientific Advisor |
| Mary Kay Turner | Senior Vice President of Patient Advocacy and Government Affairs |
| Dr. Netta Blondheim-Shraga Ph.D. | Senior Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 21, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 21, 2025 | 8-K | Current Report |
| Jan 15, 2025 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |